Related references
Note: Only part of the references are listed.The efficacy of ibrutinib in the treatment of Richter syndrome
Mazie Tsang et al.
BLOOD (2015)
Ibrutinib and rituximab induced rapid response in refractory Richter syndrome
Zanetta Lamar et al.
CLINICAL CASE REPORTS (2015)
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
Anas Younes et al.
LANCET ONCOLOGY (2014)
Risk Factors for Richter Syndrome in Chronic Lymphocytic Leukemia
Sameer A. Parikh et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2014)
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
Ekaterina Chigrinova et al.
BLOOD (2013)
Clinical implications of the molecular genetics of chronic lymphocytic leukemia
Robin Foa et al.
HAEMATOLOGICA (2013)
Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia
Jacqueline Barrientos et al.
LEUKEMIA & LYMPHOMA (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Share Paper
